Dr. Henry Brenman Returns to Biosonics, Inc.

FORT WASHINGTON, Pa.--(BW HealthWire)--July 28, 1999--

Biosonics, Inc. (OTCBB:BISN), announced today that Dr. Henry S. Brenman, co-founder of Biosonics and the originator of its medical devices, returns to the company as a consultant to widen applications for all Biosonics' products.

Dr. Brenman, who founded Biosonics in 1980 together with the late Jack Paller, formerly was the company's Director of Research and Development. He has 30 years of experience in electro-physiology and associated fields, and has presented and authored over 100 scientific papers. He is a former associate professor of physiology at the Thomas Jefferson University School of Medicine in Philadelphia.

"I am very excited about returning to active status with Biosonics. Working together with an experienced, goal-oriented team focused on widening the field of applications for our technology is a unique opportunity for creativity," Dr. Brenman said.

Dr. Brenman, who has been involved in the development and patenting of some 26 medical devices, including eight patents owned by Biosonics. The patents held by Biosonics include the Salitron for dry mouth, Cystotron for incontinence, Nasotron for nasal/sinus congestion, the MEGS for erectile dysfunction, and the BIDDS Glove, a medical diagnostic tool.

"We welcome Dr. Brenman back to Biosonics," said Sandra Pileggi, Biosonics Vice President. "He is an important resource that will enable Biosonics' product development team to further create and produce electrotherapeutic solutions to increase the quality of life for millions of men and women."

All statements contained in the press release are not historical facts, including but not limited to the Company's plans for product development and marketing, are based on current expectations. These statements are forward looking (as defined in the US Private Securities Litigation Reform Act of 1995 and the Act) in nature and involve a number of risks and uncertainties.

The factors that could cause actual results to vary materially include the availability of capital to finance operations on terms satisfactory to the company and the availability of clearances or approvals of product by federal, state and foreign government authorities.